MCID: KHN001
MIFTS: 48

Kuhnt-Junius Degeneration

Categories: Eye diseases

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 12 15
Neovascular Age-Related Macular Degeneration 12 15
Susceptibility to Neovascular Type of Age-Related Macular Degeneration 6
Exudative Senile Macular Degeneration of Retina 12
Exudative Age-Related Macular Degeneration 74
Wet Senile Macular Retinal Degeneration 12
Senile Macular Degeneration, Wet 12
Exudative Macular Degeneration 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10873
ICD9CM 36 362.52
SNOMED-CT 69 11290001 16018000
ICD10 34 H35.32

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary : Kuhnt-Junius Degeneration, also known as neovascular age-related macular degeneration, is related to yemenite deaf-blind hypopigmentation syndrome and central serous chorioretinopathy. An important gene associated with Kuhnt-Junius Degeneration is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways/superpathways are VEGF Pathway (Qiagen) and Signaling events mediated by VEGFR1 and VEGFR2. The drugs Ranibizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotype is vision/eye.

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 yemenite deaf-blind hypopigmentation syndrome 30.9 CFH VEGFA
2 central serous chorioretinopathy 30.9 ARMS2 CFH
3 retinal vascular disease 30.1 PGF VEGFA
4 macular degeneration, age-related, 1 28.0 ARMS2 CFH CFHR4 HTRA1 PGF SHROOM3
5 macular degeneration, age-related, 12 10.6
6 cataract 10.5
7 macular holes 10.5
8 macular retinal edema 10.4
9 salla disease 10.4
10 diabetic macular edema 10.4
11 charles bonnet syndrome 10.4
12 macular degeneration, age-related, 2 10.3
13 microvascular complications of diabetes 5 10.3
14 macular degeneration, age-related, 6 10.3
15 vitreous detachment 10.3
16 cytokine deficiency 10.3
17 degos 'en cocarde' erythrokeratoderma 10.3
18 dense deposit disease 10.2 CFH CFHR2
19 retinal drusen 10.2 ARMS2 CFH
20 histoplasmosis 10.1 ARMS2 CFH
21 macular dystrophy, dominant cystoid 10.1
22 parkinson disease, late-onset 10.1
23 pseudoxanthoma elasticum 10.1
24 insulin-like growth factor i 10.1
25 homocysteinemia 10.1
26 coronary heart disease 1 10.1
27 neuropathy, hereditary, with or without age-related macular degeneration 10.1
28 macular degeneration, age-related, 14 10.1
29 pemphigus foliaceus 10.1
30 open-angle glaucoma 10.1
31 heart disease 10.1
32 dementia 10.1
33 mental depression 10.1
34 vascular disease 10.1
35 impotence 10.1
36 endophthalmitis 10.1
37 herpes zoster 10.1
38 psoriasis 10.1
39 ocular hypertension 10.1
40 herpes zoster ophthalmicus 10.1
41 macular telangiectasia type 2 10.1
42 depression 10.1
43 cytomegalovirus infection 10.1
44 neovascular glaucoma 10.1 PGF VEGFA
45 epithelioid hemangioendothelioma 10.1 PGF VEGFA
46 cancer-associated retinopathy 10.1 PGF VEGFA
47 retinal vascular occlusion 10.1 PGF VEGFA
48 multifocal choroiditis 10.1 ARMS2 CFH HTRA1
49 choroiditis 10.1 ARMS2 CFH HTRA1
50 limb ischemia 10.0 PGF VEGFA

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.1 CFH HTRA1 PGF VEGFA VEGFB VLDLR

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 347396-82-1 459903
2
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
4
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
5
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
6
Lactitol Investigational Phase 4,Not Applicable 585-86-4, 585-88-6 493591
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Immunoglobulins Phase 4,Phase 2,Phase 1
9 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antibodies, Monoclonal Phase 4,Phase 2,Phase 1
11 Antibodies Phase 4,Phase 2,Phase 1
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Autoantibodies Phase 4
21 Ketorolac Tromethamine Phase 4
22 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
24 Cyclooxygenase Inhibitors Phase 4
25 Analgesics Phase 4,Phase 2,Not Applicable
26 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Not Applicable
28 Omega 3 Fatty Acid Phase 4,Not Applicable
29 Pyranoprofen Phase 4,Not Applicable
30 Tocolytic Agents Phase 4
31
Triamcinolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
32
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
33
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
34
tannic acid Approved Phase 3,Phase 2 1401-55-4
35
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
36
Timolol Approved Phase 2, Phase 3 26839-75-8 33624 5478
37
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 3154 5284549
38
Povidone Approved Phase 3 9003-39-8
39
Iodine Approved, Investigational Phase 3 7553-56-2 807
40
Povidone-iodine Approved Phase 3 25655-41-8
41
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
42 Squalamine Investigational Phase 3,Phase 2 148717-90-2
43 Anecortave Investigational Phase 3,Phase 2,Phase 1 10184-70-0
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
49 triamcinolone acetonide Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 332)
# Name Status NCT ID Phase Drugs
1 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
2 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
3 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
4 Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD Unknown status NCT01213667 Phase 4 Ranibizumab
5 Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 Unknown status NCT01961414 Phase 4 Aflibercept
6 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
7 A Study Comparing Efficacy and Safety of "Treat-and-Extend" Regimen Versus PRN of Conbercept in AMD Unknown status NCT02802657 Phase 4 Conbercept
8 A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
9 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Unknown status NCT02689518 Phase 4 Intravitreal aflibercept injection
10 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
11 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) Completed NCT01988662 Phase 4
12 Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration Completed NCT02843490 Phase 4 Ranibizumab
13 Intravitreal Aflibercept for Submacular Hemorrhage Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
14 Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
15 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept Completed NCT02125864 Phase 4 Aflibercept
16 Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor Completed NCT01896284 Phase 4 0.5mg aflibercept
17 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START Completed NCT02246829 Phase 4
18 Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
19 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed NCT02161575 Phase 4 Ranibizumab
20 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4 Ranibizumab
21 Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Completed NCT02944227 Phase 4 Lucentis
22 Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
23 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
24 LUCAS (Lucentis Compared to Avastin Study) Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
25 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
26 Single or Combined Protocols for NV-AMD Completed NCT03552770 Phase 4 Bevacizumab
27 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
28 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
29 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
30 Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) Completed NCT02142296 Phase 4 Eylea
31 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
32 Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Completed NCT02257632 Phase 4 Ranibizumab;Aflibercept
33 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
34 Ranibizumab Plus Indomethacin Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
35 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept Completed NCT01617148 Phase 4 Aflibercept
36 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
37 Study EvAluating Genotypes While Using Lucentis 2 Completed NCT01464723 Phase 4 Ranibizumab
38 Head to Head Study of Anti-VEGF Treatment. Completed NCT02577107 Phase 4 ranibizumab;Conbercept
39 Study for Recalcitrant Age Related Macular Degeneration Completed NCT01543568 Phase 4 aflibercept 2.0 mg
40 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
41 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. Recruiting NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
42 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Recruiting NCT02976194 Phase 4 ranibizumab
43 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye Active, not recruiting NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
44 PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
45 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Not yet recruiting NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
46 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
47 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4 Intravitreal aflibercept
48 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
49 A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD) Terminated NCT00312351 Phase 4 Pegaptanib sodium
50 Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Terminated NCT00134667 Phase 4 Photodynamic Therapy (PDT) with Visudyne (verteporfin);Macugen (pegaptanib sodium)

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

MalaCards organs/tissues related to Kuhnt-Junius Degeneration:

42
Eye, Endothelial, Retina, Testes, Monocytes, T Cells, Bone

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

(show top 50) (show all 1399)
# Title Authors Year
1
Effect of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients: a pilot study. ( 30203451 )
2019
2
Long-Term Regular Use of Low-Dose Aspirin and Neovascular Age-Related Macular Degeneration: National Sample Cohort 2010-2015. ( 30240791 )
2019
3
Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trial. ( 29930098 )
2019
4
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study. ( 30401482 )
2019
5
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. ( 30341774 )
2019
6
Plasma markers of chronic low-grade inflammation in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. ( 30288946 )
2019
7
Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. ( 30281212 )
2019
8
Intravitreal conbercept injection for neovascular age-related macular degeneration. ( 30809481 )
2019
9
Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration. ( 30806775 )
2019
10
Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). ( 30803522 )
2019
11
Utility of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. ( 30797883 )
2019
12
Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration. ( 30796269 )
2019
13
Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness. ( 30793798 )
2019
14
Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. ( 30788433 )
2019
15
Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States. ( 30768224 )
2019
16
Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept. ( 30767090 )
2019
17
Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. ( 30740921 )
2019
18
OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy. ( 30689620 )
2019
19
GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ( 30681643 )
2019
20
Changes in macular drusen parameters preceding the development of neovascular age-related macular degeneration. ( 30679872 )
2019
21
Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. ( 30679743 )
2019
22
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. ( 30676617 )
2019
23
In vivo diagnosis of intraocular osseous metaplasia in neovascular age-related macular degeneration. ( 30672503 )
2019
24
Extended (≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials. ( 30664844 )
2019
25
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. ( 30664640 )
2019
26
Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis. ( 30641096 )
2019
27
Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. ( 30618282 )
2019
28
Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease? ( 30617582 )
2019
29
Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye. ( 30617580 )
2019
30
Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration. ( 30585922 )
2019
31
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. ( 30912953 )
2019
32
Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations. ( 30911999 )
2019
33
Long-Term Changes in Submacular Choroidal Thickness After Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up. ( 30909756 )
2019
34
Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. ( 30901385 )
2019
35
Subfoveal choriocapillaris, Sattler's and Haller's layer thickness predict clinical response to stereotactic radiotherapy in neovascular age-related macular degeneration patients. ( 30899853 )
2019
36
Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration. ( 30892159 )
2019
37
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better. ( 30858684 )
2019
38
Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. ( 30844038 )
2019
39
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. ( 30842468 )
2019
40
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. ( 30834517 )
2019
41
ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ( 30821728 )
2019
42
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials. ( 29280937 )
2019
43
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. ( 29370035 )
2018
44
OCT Angiography Helps Distinguish Between Proliferative Macular Telangiectasia Type 2 and Neovascular Age-Related Macular Degeneration. ( 29772040 )
2018
45
Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. ( 29550186 )
2018
46
Neovascular age-related macular degeneration is associated with cataract surgery. ( 28671319 )
2018
47
Effect of cataract surgery in patients with neovascular age-related macular degeneration: further evidence from disciform scars. ( 28255836 )
2018
48
QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ( 28492427 )
2018
49
Increased risk of neovascular age-related macular degeneration in patients with herpes zoster ophthalmicus: a retrospective cohort study. ( 30218493 )
2018
50
The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. ( 30451182 )
2018

Variations for Kuhnt-Junius Degeneration

ClinVar genetic disease variations for Kuhnt-Junius Degeneration:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh37 Chromosome 10, 124220544: 124220544
2 HTRA1 NM_002775.4(HTRA1): c.-625G> A single nucleotide variant risk factor rs11200638 GRCh38 Chromosome 10, 122461028: 122461028

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 CFH HTRA1 PGF VEGFA VEGFB VLDLR
2 extracellular region GO:0005576 9.17 CFH CFHR2 CFHR4 HTRA1 PGF VEGFA

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.7 PGF VEGFA VEGFB
2 positive regulation of protein phosphorylation GO:0001934 9.69 PGF VEGFA VEGFB
3 response to hypoxia GO:0001666 9.67 PGF VEGFA VEGFB
4 positive regulation of angiogenesis GO:0045766 9.65 PGF VEGFA VEGFB
5 regulation of complement activation GO:0030449 9.63 CFH CFHR2 CFHR4
6 positive regulation of endothelial cell proliferation GO:0001938 9.61 PGF VEGFA VEGFB
7 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.58 PGF VEGFA VEGFB
8 positive regulation of epithelial cell proliferation GO:0050679 9.54 HTRA1 VEGFA
9 positive chemotaxis GO:0050918 9.54 PGF VEGFA VEGFB
10 positive regulation of cell division GO:0051781 9.5 PGF VEGFA VEGFB
11 sprouting angiogenesis GO:0002040 9.43 PGF VEGFA VEGFB
12 vascular endothelial growth factor signaling pathway GO:0038084 9.33 PGF VEGFA VEGFB
13 induction of positive chemotaxis GO:0050930 9.13 PGF VEGFA VEGFB
14 positive regulation of mast cell chemotaxis GO:0060754 8.8 PGF VEGFA VEGFB

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.71 CFHR2 PGF VEGFA VEGFB
2 protein heterodimerization activity GO:0046982 9.67 CFHR2 PGF VEGFA VEGFB
3 growth factor activity GO:0008083 9.5 PGF VEGFA VEGFB
4 heparin binding GO:0008201 9.46 CFH PGF VEGFA VEGFB
5 chemoattractant activity GO:0042056 9.13 PGF VEGFA VEGFB
6 vascular endothelial growth factor receptor 2 binding GO:0043184 8.96 VEGFA
7 vascular endothelial growth factor receptor 1 binding GO:0043183 8.62 VEGFA VEGFB

Sources for Kuhnt-Junius Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....